Intercell completed Acquisition of Antibody Technology Platform from Cytos

Intercell AG, a public biotechnology company specialized in the development of novel vaccines for the prevention and treatment of infectious diseases, completed the acquisition of the platform technology for monoclonal antibody discovery from SIX-listed Cytos Biotechnology Ltd. The technology is based on expression of cloning of monoclonal antibodies from human B-cells and enables the identification of anti-infective antibodies to prevent and treat infectious diseases. Intercell acquired in this transaction certain unpartnered monoclonal antibody assets and the key scientists who have developed the technology are now employed by Intercell.

Lenz & Staehelin advised Intercell in this transaction. The team included Beat Kühni (M&A, Corporate), Thierry Calame (IP), Maja Baumann and Liv Droz (both M&A, Corporate), and Ruedi Ackermann.